Genetic and Metabolic Disease in Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02650622|
Recruitment Status : Recruiting
First Posted : January 8, 2016
Last Update Posted : June 24, 2021
|Condition or disease||Intervention/treatment|
|Genetic Diseases Metabolic Diseases||Procedure: Skin Biopsy|
Discovery of genetic basis of impaired metabolism has greatly advanced treatment of patients with known metabolic diseases. However, many more genetic and metabolic disorders and their molecular causes remain to be discovered. The overall goal of this study is to discover new disease-associated genes in children, while establishing a specific focus on metabolic disorders where molecular characterization is most likely to lead to novel therapies. The primary objective is to identify novel pathogenic mutations in children with rare Mendelian disorders. The secondary objectives are: 1) Optimize methodology for metabolomic sample collection, processing and analysis; and 2) Establish normative ranges for a large number (potentially up to 1000) of metabolites in healthy newborns and older children.
Approximately one in three admissions to tertiary care pediatric hospitals results from conditions with a genetic basis. Although the majority of these conditions are rare, they collectively account for a disproportionate amount of illness and death in children. Discovery of the genetic basis of rare conditions often uncovers the pathophysiological basis of common diseases. This is particularly true for genetic diseases of impaired metabolism (inborn errors of metabolism, IEMs). There are many more genetic and metabolic disorders yet to be discovered. Of approximately 20,000 known human genes, less than one-fifth are currently associated with a disease phenotype. IEMs are a particular area of focus for us for two major reasons. First, of the several hundred known IEMs, many are already effectively treated with dietary modifications and/or medical therapy. This indicates to us that discovery of new IEM genes has great potential to produce clinically actionable insights into pathophysiology and therapeutic opportunities, ultimately leading to treatment of children that would otherwise be impossible to treat. Second, the PI of this study, Dr. Ralph DeBerardinis, is an expert in metabolomics, the practice of identifying and quantifying metabolites from biological systems. We will therefore implement research-based metabolomic profiling to the evaluation of patients with suspected IEMs or other genetic diseases. This detailed analysis will substantially increase the likelihood of identifying clinically relevant metabolic perturbations in children with growth failure, acidosis, hypoglycemia, hyperammonemia, and other abnormalities of putative genetic origin. It would also enable us to interpret mutations uncovered by clinical or research-based genomic sequencing. We believe that establishing a systematic procedure to evaluate both the metabolome and the genome in sick children will produce new insights into the genetic basis of pediatric disease, and ultimately new ways to treat these conditions.
In this study, subjects will be recruited as two populations: control and diseased. In the control population, plasma samples of healthy newborns will be acquired at the time of blood collection for state-mandated newborn screening from Parkland. We will also collect blood from healthy children from the clinics at Children's Medical Center (CMC), again piggybacking this research sample with venipuncture for clinically indicated blood collection. All plasma samples will be subjected to metabolomics to determine the healthy ranges for a large number of metabolites. This comprehensive profile of metabolites in children will be used as normative ranges to identify outlying metabolites in diseased subjects. Additionally, if suspected metabolic outliers are detected from this normal population, DNA samples extracted from the leftover packed cells or blood samples will be subjected to genomic sequencing to profile the associated gene mutations. The diseased population will be recruited from the clinics of the Pediatric Genetics and Metabolism Division in the Department of Pediatrics/CMC. Blood and DNA samples will be collected from patients for metabolomic analysis and next-generation sequencing respectively to define the metabolic abnormalities and associated gene mutations. Skin fibroblasts from patients will also be collected and used for biological validation of the metabolic effects of novel mutations, in particular by complementing diseased fibroblasts with wild-type alleles of genes mutated in the patient. If any rare Mendelian disorder is considered in a subject, blood from his/her family members will be acquired and subjected to metabolomic and genomic analyses to facilitate identification of the diseased-associated genes.
|Study Type :||Observational|
|Estimated Enrollment :||1550 participants|
|Official Title:||Genetic Regulators of Metabolism and Development in Children|
|Actual Study Start Date :||June 2015|
|Estimated Primary Completion Date :||May 2025|
|Estimated Study Completion Date :||May 2025|
Cohort 1-Newborns aged 1-2 days
No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the state-mandated newborn screening test.
Cohort 2-Children aged 0-18 years
No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care.
Cohort 3-Diseased childrens and families
Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care. Skin biopsy will be performed on the proband children with the agreement from parents or guardians.
Procedure: Skin Biopsy
Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
- Perform metabolomic profiling and exome sequencing in children with presumed genetic and metabolic diseases [ Time Frame: 3-4 years ]The Levels of the metabolites that can be detected in the plasma from the enrolled children will be measured by mass-spectrometry technique.The DNA samples will be extracted from the blood samples of diseased children and then subjected to exome sequencing to identify gene mutations.
- Perform metabolomic profiling in healthy children [ Time Frame: 3-4 years ]The Levels of the metabolites will be measured by by mass-spectrometry technique in the plasma samples from enrolled healthy children.
- Establish a specimen repository of healthy and diseased children [ Time Frame: 3 years ]Blood samples and derived plasma and DNA samples, and patient fibroblast cell lines will be de-identified and stored in research laboratory.
Biospecimen Retention: Samples With DNA
There are 3 cohorts in this study:
Cohort 1: healthy newborns Cohort 2: healthy children aged 0-18 years old Cohort 3: Children with genetic/metabolic disorders and their families
Blood samples will be collected from all the three cohorts for isolation of plasma for metabolomic analysis.
In addition, DNA will be extracted from the blood samples of cohort 3 patients for genomic sequencing, and skin fibroblast cells will be collected from the proband patients in cohort 3.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02650622
|Contact: Min Ni, PhDemail@example.com|
|United States, Texas|
|Children's Medical Center at Dallas||Recruiting|
|Dallas, Texas, United States, 75390|
|Contact: Donnice Michel 214-456-6148 DONNICE.MICHEL@childrens.com|
|Principal Investigator: Ralph J DeBerardinis, MD, PhD|
|Principal Investigator:||Ralph J DeBerardinis, MD, PhD||UT Southwestern Medical Center, Children's Medical Center at Dallas|